| Placebo | Golimumab | Ustekinumab | p-value# | |
| Patients in the lung group n | 44 | 42 | 46 | |
| ΔFVC % predicted at week 16 | ||||
| Mean±se¶ | 2.02±1.350 | 1.15±1.413 | -0.15±1.279 | 0.305 |
| 95% CI | -0.65–4.69 | -1.64–3.95 | -2.68–2.38 | |
| p-value+ | 0.543 | 0.126 | ||
| ΔFVC % predicted at week 28 | ||||
| Mean±se¶ | 1.59±1.621 | 0.29±1.679 | 0.56±1.536 | |
| 95% CI | -1.62–4.79 | -3.07–3.65 | -2.48–3.60 | |
| p-value+ | 0.451 | 0.546 | ||
| Δ6MWD at week 28 | ||||
| Mean±se¶ m | 14.52±14.223 | 12.53±14.919 | -13.22±13.584 | |
| 95% CI | -13.63–42.66 | -16.99–42.06 | -40.10–13.67 | |
| p-value+ | 0.896 | 0.063 | ||
| ΔSGRQ total score at week 28 | ||||
| Mean±se¶ | -9.50±2.790 | −6.86±2.921 | −4.25±2.662 | |
| 95% CI | -15.02– -3.98 | -12.64– -1.08) | -9.52–1.01 | |
| p-value+ | 0.374 | 0.073 | ||
| Patients in the skin group n | 20 | 17 | 21 | |
| Patients with a SPGA score ≤1 n | ||||
| Responders n (%) | 6 (30) | 9 (52.9) | 3 (14.3) | |
| p-value§ | 0.1931 | 0.2772 |
ΔFVC%: change from baseline in forced vital capacity; Δ6MWD: change from baseline in 6-min walking distance; ΔSGRQ: change from baseline in the St. George's Respiratory Questionnaire; SPGA: Skin Physician Global Assessment. #: the overall p-value is based on the F-test; ¶: means are reported as least square means; +: treatment comparisons are based on linear contrasts; §: treatment comparisons are based on Fisher's exact test.